Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

2009878 citationsReview

Authors

John Koreth · Dana-Farber Cancer Institute

Richard F. Schlenk

Frederick R. Appelbaum

Hartmut Döhner

Abstract

Compared with nonallogeneic SCT therapies, allogeneic SCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good-risk AML in first complete remission.

Topics & Keywords

Acute Myeloid Leukemia Research Hematopoietic Stem Cell Transplantation Acute Lymphoblastic Leukemia research

UN Sustainable Development Goals

No poverty

Publication Details

Published in: JAMA

Volume 301, Issue 22, pp. 2349-2349

DOI: 10.1001/jama.2009.813

Field-Weighted Citation Impact: 28.95